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ABSTRACT 
Rhinoviruses (RVs) are associated with exacerbations of cystic fibrosis (CF), asthma and 
COPD. There is growing evidence suggesting the involvement of the interferon (IFN) 
pathway in RV-associated morbidity in asthma and COPD. The mechanisms of RV-triggered 
exacerbations in CF are poorly understood. In a pilot study, we assessed the antiviral 
response of CF and healthy bronchial epithelial cells (BECs) to RV infection, we measured 
the levels of IFNs, pattern recognition receptors (PRRs) and IFN-stimulated genes (ISGs) 
upon infection with major and minor group RVs and poly(IC) stimulation. Major group RV 
infection of CF BECs resulted in a trend towards a diminished IFN response at the level of 
IFNs, PRRs and ISGs in comparison to healthy BECs. Contrary to major group RV, the IFN 
pathway induction upon minor group RV infection was significantly increased at the level of 
IFNs and PRRs in CF BECs compared to healthy BECs. 
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INTRODUCTION 
Rhinoviruses (RVs) are small positive-sense ssRNA viruses belonging to the Picornaviridae 
family. RV serotypes are classified as major or minor group depending on the surface 
receptor used to infect target cells. More than 90% of RV serotyped strains belong to the 
major group and use as receptor the intercellular adhesion molecule 1 (ICAM-1), while the 
minor group RV strains bind to low-density lipoprotein receptor (LDLR) on target cells (1, 2). 
As the causative agents of the common cold and acute respiratory tract infections in children, 
RVs are one of the major causes of morbidity and mortality (3). In addition, RVs are the 
predominant agents associated with pulmonary exacerbations of CF lung disease as they 
are detected in up to 40% of all virus-associated CF exacerbations (4-6). The mechanisms of 
acute virus-mediated exacerbations in CF are so far poorly understood. 
We and others have reported recently that primary CF bronchial epithelial cells (BECs) have 
an increased susceptibility to respiratory virus infections such as RVs and parainfluenza virus 
(7-9). We have confirmed these findings ex vivo in bronchoalveolar lavage (BAL) samples 
collected from RV-infected CF children, in which RV load was elevated in comparison to 
control patients (10). 
RVs are also responsible for more than 50% of virus-induced asthma exacerbations (11). 
Defective interferon (IFN) type I (IFN-β) and type III (IFN-λs) production of the bronchial 
airway epithelium upon RV infection has been identified as a contributing mechanism behind 
the impaired RV control in asthmatic adults and children (12-16). The work of two groups 
studying mechanisms of viral control and IFN induction in BECs and macrophages collected 
from patients with chronic obstructive pulmonary disease (COPD) led to controversial results. 
After growing BECs at air-liquid interface (ALI), Schneider et al. showed an increase in IFN 
production upon RV infection. Despite that, cells showed an impaired viral control and an 
increased pro-inflammatory phenotype (17). On the other hand, Mallia et al. found lower IFNs 
responses upon infection with RV by BAL macrophages from COPD patients compared to 
control subjects (18).  
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Since the IFN pathway is involved in the defective control of RV in infected BECs from 
asthmatic and COPD patients, we decided to evaluate the IFN response of CF BECs after 
challenging with RVs from the major and minor group (RV16 and RV1B, respectively). Also, 
we aimed to assess the baseline expression and induction of pattern recognition receptors 
(PRRs) engaged in the sensing of RV including toll-like receptor 3 (TLR3), melanoma 
differentiation-associated protein 5 (MDA5), and retinoic acid inducible gene I (RIG-I) (19). 
Levels of IFN-stimulated genes (ISGs) such as dsRNA protein kinase R (PKR), 2’-5’-
oligoadenylate synthetase 1 (OAS1), MxA (Myxovirus resistance gene A), and viperin (virus 
inhibitory protein, endoplasmic reticulum-associated, IFN inducible) were also measured. 
Finally, the inflammatory response mediated by RV infection of CF BECs has also been 
quantified through the measurement of CXCL8/IL-8, IL-6 and CXCL10/IP-10 cytokines 
release. 
 
MATERIAL AND METHODS 
Study subjects 
For the establishment of primary BEC cultures, we recruited healthy and CF volunteers at the 
University Hospitals of Bern and Zürich. The clinical characteristics of the participants used in 
this study have been presented elsewhere (9) and are reproduced here for clarity ease of 
reference (Table 1). The exclusion criteria were bleeding tendency, therapy with 
anticoagulants and/or immunosuppressive agents. For the control group steroid use within 
the past three months and atopy were additional exclusion criteria. The study was approved 
by the Ethics committees of the Cantons of Bern and Zurich, Switzerland and informed 
consent was obtained from all study participants and/or caregivers. 
 
Isolation of primary CF and control bronchial epithelial cells 
BECs from 11 CF and 12 control subjects were grown from bronchial brushings performed 
with a 3 mm brush (ConMed, USA) as described (9). 
Cell culture 
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Primary submerged cultures of BECs were obtained by seeding freshly brushed cells in 
Bronchial Epithelial Growth Medium (BEGM, Lonza, Switzerland), supplemented with Single 
Quots (Lonza, Switzerland) as described previously (9). 
 
Rhinovirus infection 
RV16 and RV1B viruses were amplified and titrated with Ohio HeLa cells (ECCAC, UK). 
BECs were infected with RVs for 1h at a multiplicity of infection of 4 and washed three times 
with PBS (Life Technologies, USA). Fresh medium was added and plates were further 
incubated at 37 ºC for 24h until harvesting. Cells were treated in parallel with infection media 
(IM) and polyinosinic-polycytidylic acid (poly(IC)) at a concentration of 1 µg/ml (Invivogen, 
USA). Since the peak of RV replication is observed at ca. 24h post-infection (20, 21), total 
RNA and supernatants were harvested at 24h post-infection for further analysis. 
 
Isolation of total RNA and RT-PCR 
Total RNA purification was done by using the Nucleospin RNA II kit (Macherey-Nagel, 
Switzerland). Synthesis of cDNA was performed with Omniscript RT Kit (Qiagen, USA) 
following the manufacturer`s protocol. RT-PCR measurements were done with the Taqman 
Fast universal PCR master mix and the Fast SYBR Green master mix on a 7500 Fast Real 
Time PCR System (all from Applied Biosystems, USA). The sequences of primers and 
probes are depicted in Table 2. To analyze the mRNA expression levels of IFNs, PRRs and 




Protein levels of CXCL8/IL-8, IL-6 and CXCL10/IP-10 were measured by using the DuoSet 
ELISA Development kit (R&D, USA) with the following detection limits: CXCL8/IL-8 15 pg/ml, 
IL-6 3 pg/ml, and CXCL10/IP-10 2 pg/ml. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software Inc., USA). 
The data were analyzed for normal distribution by using the Kolmogorov-Smirnov test. If 
normally distributed, paired data were analyzed with one-way ANOVA and the Tukey Post 
hoc test. Paired data non-normally distributed were analyzed with the Friedman and the 
Dunn’s Post hoc tests. The analysis of unpaired data was performed with a two-way ANOVA 
with the Bonferroni Post hoc test if normally distributed. Unpaired data non-normally 
distributed were analyzed with the Kruskal-Wallis test followed by a Dunn’s Post hoc test. A 
p<0.05 was considered statistically significant. Normally distributed data are shown as mean 
and SEM and non-parametric data are shown as median and IQR. 
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RESULTS 
IFNs response in CF BECs to RV infection 
In order to determine if the antiviral responses mediated by IFNs are functional in CF BECs, 
we measured mRNA expression levels of IFN-λ1, IFN-λ2/3 and IFN-β in CF and control 
BECs infected with RV16 and RV1B. After infection of CF BECs with major group RV, we 
observed a non-significant trend towards lower levels of IFN-λ1 (Figure 1A), IFN-λ2/3 (Figure 
1B), and IFN-β (Figure 1C) in comparison to healthy BECs. In contrast, the IFN responses of 
CF BECs compared to healthy BECs upon infection with minor group RV were significantly 
increased for IFN-λ1 (Figure 1A) and IFN-λ2/3 (Figure 1B). We observed no difference for 
the experiments with poly(IC) - a strong IFN inducer – which gave similar levels of all the 
measured IFNs between CF BECs and healthy BECs (Figure 1A-C). 
 
PRRs expression upon RV infection in CF BECs 
Next, we evaluated the expression of the PRRs involved in the sensing and innate immune 
response to RVs. The constitutive mRNA levels of the viral sensors TLR3, RIG-I and MDA5 
were not different in CF compared to control cells (data not shown). We observed a non-
significant trend towards a decreased expression of RIG-I (Figure 2B) and MDA5 (Figure 2C) 
upon infection with the major group virus RV16 in CF cells compared to controls. 
Interestingly, in CF BECs infected with RV1B, the level of RIG-I was significantly increased 
(Figure 2B), and we found a trend towards an elevated expression of TLR3 (Figure 2A) in 
comparison to healthy BECs. Interestingly, poly(IC) stimulation of CF BECs induced a 
significantly higher level of all the PRRs tested in CF BECs in comparison to healthy BECs 
(Figure 2A-C). 
 
Induction of ISGs upon infection in CF BECs 
In infected cells, activation of PRRs and subsequent IFN production launches an antiviral 
effector mechanism leading to the expression of numerous ISGs. Thus, we analyzed the 
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expression of selected ISGs, namely PKR, OAS1, viperin and MxA upon RVs infection and 
poly(IC) stimulation. We found a significantly lower expression of viperin (Figure 3C) and a 
tendency to a lower expression of MxA (Figure 3D) in CF vs. healthy BECs infected with 
RV16. Also, there was a significantly higher expression of PKR (Figure 3A) and MxA (Figure 
3D) in CF BECs stimulated with poly(IC) in comparison to controls. We observed no 
difference in the ISGs tested between CF and healthy BECs infected with minor group RV1B 
(Figure 3A-D). 
 
Pro-inflammatory cytokine responses of CF BECs to RV infection 
In order to evaluate the inflammatory response of CF BECs after RV infection, we measured 
the levels of CXCL8/IL-8, IL-6 and CXCL10/IP-10 cytokines under baseline condition and 
upon infection with RV16, RV1B and stimulation with poly(IC). The inflammatory cytokines 
produced by BECs upon RVs infection and/or poly(IC) stimulation were generally increased 
in CF cells. Indeed, CXCL8/IL-8 levels had the non-significant tendency to be constitutively 
higher and significantly increased upon poly(IC) treatment (Figure 4A) in CF cells compared 
to controls. Also, in comparison to control BECs, CF BECs had significantly higher levels of 
IL-6 under baseline condition and after poly(IC) stimulation (Figure 4B). The CXCL10/IP-10 
levels produced by CF BECs were significantly higher at baseline in comparison to control 
BECs. In contrast to IL-8 and IL-6, CF BECs produced significantly less CXCL10/IP-10 in 
comparison to control BECs stimulated with poly(IC) (Figure 4C). 
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DISCUSSION 
RV infections have been associated with pulmonary exacerbations of asthma, COPD and CF 
lung disease. There is growing evidence that an impaired antiviral response mediated by the 
IFN pathway may contribute to the increased susceptibility towards RV infection of asthmatic 
(12, 13, 16) and COPD (17, 18, 23) patients. In order to determine if the IFN pathway is also 
playing a role in the RV-associated morbidity of the CF lung disease, we used primary 
cultures of CF and healthy BECs. The expression levels of IFN-λ1 and IFN-λ2/3 in CF BECs 
infected with RV1B were higher than the levels found in healthy BECs. Also, primary CF and 
healthy BECs stimulated with poly(IC) gave similar IFN levels. However, we observed a trend 
towards lower RV16-induced levels of IFN-λ1, IFN-λ2/3 and IFN-β in CF BECs in comparison 
to healthy BECs. This observation is in line with the results from Chattoraj et al who reported 
a decreased IFN response in CF BECs in comparison to healthy BECs after infection with 
major group RV. Interestingly, the IFN response of CF BECs was even lower after co-
infection with P. aeruginosa and major group RV (24). Also, the same authors suggest that 
RV infection of CF patients is exacerbating lower airway symptoms by promoting the 
outgrowth of P. aeruginosa (25). Interestingly, Stelzer-Braid et al. reported recently that most 
of CF pulmonary exacerbations triggered by RVs are not associated with the presence of 
bacterial pathogens as assessed by multiplex RT-PCR (26). Thus, the exact contribution and 
the mechanism of P. aeruginosa in RV-induced exacerbation of CF deserve further 
investigation. 
 
The level of PRRs engaged in the sensing of RVs (19, 27) were measured upon infection of 
major and minor group RVs and after poly(IC) stimulation. In line with the decreased IFN 
responses of CF BECs infected with major group RV, we observed a non-significant trend 
towards a decreased induction of TLR3, RIG-I, and MDA5 in CF BECs in comparison to 
healthy BECs after infection with major group RV. Interestingly, we found a higher induction 
of TLR3, RIG-I, and MDA5 in CF vs. healthy BECs upon treatment with the IFN inducer 
poly(IC). At the level of ISGs, we observed a decreased induction of viperin and MxA in CF 
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BECs in comparison to healthy BECs after infection with minor group RV. This observation is 
in accordance with our finding of impaired IFNs and PRRs expressions upon RV16 infection 
in CF BECs compared to controls. The baseline and RV infection-induced ISGs expressions 
were similar in CF and healthy BECs challenged with minor group RV. Consistent with the 
increased PRRs levels induced by poly(IC) treatment, poly(IC) treatment of CF BECs led 
also to a higher expression of some of the ISGs tested such as PKR and MxA, suggesting a 
dysfunction in the signaling pathways involving dsRNA PPRs such as TLR3. To our 
knowledge, this the first report describing a hyperresponsiveness of CF cells to PRRs 
stimulation. 
 
While the infection of CF BECs with major and minor group RV exert opposite IFN responses 
in comparison to healthy BECs, the elevated inflammatory response triggered by infection 
was similar for major and minor group RVs. The inflammatory cytokines produced by CF 
BECs upon poly(IC) stimulation were altered as demonstrated by the elevated levels of the 
pro-inflammatory cytokines CXCL8/IL-8 and IL-6. Also, we found an increased constitutive 
release of CXCL8/IL-8, IL-6 and CXCL10/IP-10 by CF BECs compared to healthy BECs. 
This observation is in accordance with previous reports attributing an intrinsic inflammatory 
phenotype to CF airway cells (7, 28), and is compatible with our ex vivo data showing 
elevated inflammatory cytokine concentrations in BALs of stable CF patients (10). In line with 
the elevated PRRs and ISGs of CF BECs stimulated with poly(IC), poly(IC) stimulation led to 
a hyper-inflammatory response of CF BECs in comparison to healthy BECs as evidenced by 
the elevated levels of CXCL8/IL-8 and IL-6. However, since both cytokines are constitutively 
elevated in CF BECs, it is unclear yet if the increased inflammatory response of CF BECs to 
poly(IC) is solely due to poly(IC) stimulation or as an additive effect to the already elevated 
baseline levels of CXCL8/IL-8 and IL-6. Additional experiments are required with other 
inflammatory stimuli in order to address this question. In contrast to IL-8 and IL-6, 
CXCL10/IP-10 levels upon stimulation with poly(IC) were significantly decreased in CF cells 
in comparison to control cells. This observation is possibly explained by the fact that the 
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regulation of the CXCL10/IP-10 gene transcription is under the control of the IFN pathway 
(29, 30). 
 
In healthy cells, the responses to major and minor group RVs have been evaluated by a few 
groups. A study by Wang et al. gave similar antiviral responses of healthy BECs to RV1B 
and RV39 (27). In line with our data, it was reported by two other groups that minor group RV 
is a higher inducer of IFN-λs and IFN-β in comparison to major group RV (20, 31). Recently, 
Schuler et al. found that major and minor group RVs induced a distinct antiviral signaling and 
inflammatory cytokine responses in primary healthy macrophages (32). 
 
While RVs are the most frequently detected viruses during virus-induced CF exacerbation, 
there is a growing number of studies reporting that several viral pathogens can trigger CF 
exacerbation in children and adults including influenza virus, respiratory syncytial virus, 
parainfluenza virus, coronavirus, adenovirus and metapneumovirus (4, 33-36). All these 
viruses are inducing distinct pathogenesis in the lung and it is therefore conceivable that the 
mechanisms of virus-induced CF exacerbation are at least in part virus-specific. In line with 
this hypothesis, a recent study by Ramirez et al. demonstrated that CF exacerbations 
triggered by RV or influenza virus led to a distinct antiviral response (37). Therefore, it would 
be interesting to test our in vitro system with other clinically relevant respiratory viruses such 
as influenza and respiratory syncytial virus. 
 
In summary, we report a differential IFN pathway response of CF BECs after infection with 
major and minor group RVs. Major group RV infection is leading to a diminished IFN pathway 
response at the level of IFNs, PRRs, and ISGs. However, IFN pathway induction in CF BECs 
upon minor group RV infection was higher than in healthy BECs. Also, CF BECs have an 
intrinsic inflammatory phenotype as assessed by the constitutive elevated release of 
CXCL8/IL-8 and IL-6 and CXCL10/IP-10 cytokines. Finally, since our study is based on a 
small number of subjects, our data need further confirmation in a large study population. 
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FIGURE LEGENDS 
Figure 1. IFN responses of CF and control BECs to RV infection. (A) IFN-λ1, (B) IFN-
λ2/3 and (C) IFN-β mRNA levels measured 24h post infection by RT-PCR in CF and control 
BECs. IM (infection media), pIC (poly(IC)). The mRNA levels are represented as relative fold 
increase to mock infection (IM). Significant differences between conditions (IM, RV16, RV1B, 
pIC) are indicated by stars above error bars and are relative to the mock infection controls 
(IM). Significant differences between groups (control and CF) are indicated by horizontal 
lines. Stars indicate significance levels, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
Figure 2. PRRs expression in CF and control BECs upon RV infection. (A) TLR3, (B) 
RIG-I and (C) MDA5 mRNA levels measured in cell lysates of primary CF and control BECs 
24h post infection. IM (infection media), pIC (poly(IC). The mRNA levels are represented as 
relative fold increase to mock infection (IM). Significant differences between conditions (IM, 
RV16, RV1B, pIC) are indicated by stars above error bars and are relative to the mock 
infection controls (IM). Significant differences between groups (control and CF) are indicated 
by horizontal lines. Stars indicate significance levels, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
Figure 3. ISGs levels upon RV infection of CF and control BECs. (A) PKR), (B) OAS1, 
(C) viperin and (D) MxA mRNA levels measured in cell lysates of primary CF and control 
BECs 24h post infection. IM (infection media), pIC (poly(IC). The mRNA levels are 
represented as relative fold increase to mock infection (IM). Significant differences between 
conditions (IM, RV16, RV1B, pIC) are indicated by stars above error bars and are relative to 
the mock infection controls (IM). Significant differences between groups (control and CF) are 
indicated by horizontal lines. Stars indicate significance levels, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 4. Pro-inflammatory cytokine response of CF and control BECs upon RV 
infection. (A) IL-6, (B) IL-8 and (C) IP-10 protein levels were assessed in CF and control 
BECs by ELISA at 24h post infection. IM (infection media), pIC (poly(IC). Significant 
differences between conditions (IM, RV16, RV1B, pIC) are indicated by stars above and are 
relative to the mock infection control (IM). Significant differences between groups (control 








Table 1: Demographic and clinical characteristics of study subjects 
Control Gender Age (yrs) Atopy# Steroid use¶    
1 m 13 no no    
2 f 8 no no    
3 f ND no no    
4 m 11 no no    
5 f 3 no no    
6 m 11 no no    
7 m 3 no no    
8 f 15 no no    
9 f 3 no no    
10 m 16 no no    
11 f 13 no no    
12 m 2 no no    
        
CF Gender Age (yrs) Atopy# Steroid use¶ FEV1 % P. aeruginosa colonization* Genotype 
1 m 8 no yes 101 no F508del/R347P 
2 m 4 no no 108 no F508del/F508del 
3 f 5 no no ND yes F508del/2347delG 
4 f 11 yes no 67 no G542X/2708del13 
5 m 9 yes yes 106 no F508del/F508del 
6 m 3 no yes ND yes F508del/F508del 
7 f 9 yes no 81 no F508del/F508del 
8 m 1 no no ND no F508del/F508del 
9 f 15 yes yes 38 yes F508del/F508del 
10 m 6 no no 127 no F508del/F508del 
11 m 11 no no 62 no ND 
PA: Pseudomonas aeruginosa 
     m: male; f: female 
      ND: not determined 
      #: defined as positive history of hay fever, eczema or asthma 
  ¶: defined as any treatment with systemic, inhaled or nasal steroids within the past 3 months 
*: defined as at least one PA-positive oropharyngeal culture during the preceding 12 months 
 
 











 FW GGACGCCTTGGAAGAGTCACT 	
IFN-λ1 RV AGAAGCCTCAGGTCCCAATTC 	











  FW AAATTAAAGAGTTTTCTCCAGGGTGTT 
	
TLR3 RV ATTCCGAATGCTTGTGTTTGC 






  FW GATTCAGGCACCATGGGAAGT 
	MDA5 P FAM-GGGATGCTCTTGCTGCCACATTCTCTT-TAMRA 
	





















FW: forward ; RV: reverse ; P: probe 
	 
 
 




